Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …

Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in
several fields of medicine to prevent or treat venous and arterial thromboembolism …

Summary Background Asundexian (Bayer AG, Leverkusen, Germany), an oral small
molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding …

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent
thromboembolic events without substantially increasing bleeding. We explored the …

Importance Mendelian randomization (MR) is a statistical approach that has become
increasingly popular in the field of cardiovascular disease research. It offers a way to infer …

The objective of this review is to provide an update on the fluorine-containing drugs
approved by US Food and Drug Administration in the span of past five years (2018–2022) …

Background Clinical complexity is common in atrial fibrillation (AF) patients. We assessed
the impact of clinical complexity on oral anticoagulant (OAC) treatment patterns and major …

Introduction Stroke is one of the leading causes of mortality and morbidity globally. Atrial
fibrillation (AF) is the most common sustained cardiac arrhythmia. It is set to reach epidemic …

Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

Abstract Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in
anticoagulation because it is involved primarily in thrombus formation and plays a much …